Mar 1, 2026 06:49PM

Aug 29, 2025 05:00PM

Aug 17, 2025 07:11PM

May 28, 2025 03:45AM

Nov 21, 2024 08:00AM

Feb 28, 2024 06:30PM

Oct 25, 2023 05:25PM EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONA

Oct 15, 2023 08:02PM

Sep 25, 2023 01:17AM

Jul 11, 2023 07:30PM

Jul 6, 2023 08:00PM

Jun 11, 2023 08:13PM

Jun 9, 2023 06:45PM

Jun 7, 2023 11:32PM Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea

May 15, 2023 07:27PM

Apr 3, 2023 11:23PM

Apr 3, 2023 07:30PM

Mar 30, 2023 07:30PM

Mar 22, 2023 07:30PM

Mar 19, 2023 07:30PM

Mar 13, 2023 03:00PM U.S. VETERANS' HEALTH ADMINISTRATION (VHA) PROVIDES COVERAGE OF LEQEMBI™ (LECANEMAB-IRMB) TWO MONTHS AFTER LEQEMBI'S FDA ACCELERATED APPROVAL FOR VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER'S DIS

Mar 5, 2023 06:30PM

Jan 6, 2023 02:30PM

Jun 3, 2022 02:37AM

Jun 2, 2022 07:30PM

Sep 27, 2021 07:30PM

Jun 30, 2021 09:43PM

Jun 23, 2021 04:07PM Eisai, Biogen (BIIB) Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease

Jun 23, 2021 04:06PM

67,542 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All